MD+DI honors Xeridiem with 2011 Medical Design Excellence Award

Xeridiem™ Medical Devices (xeridiem) is a recipient of MD+DI 's 2011 Medical Design Excellence Award (MDEA).  This international award was for a novel chest tube, the PleuraFlow Active Tube Clearance System (PleuraFlow ATC), developed by Clear Catheter Systems and the Carbon Design Group.  Xeridiem orchestrated the design and development for manufacturability, supported the regulatory submission, as well as manages the supply chain including order fulfillment.  

PleuraFlow minimizes chest tube clogging during heart and lung surgery.  Independent investigators in a recent Cleveland Clinic study published by the Annals of Thoracic Surgery compared drainage from a large diameter (32 Fr) standard chest tube and that from PleuraFlow ATC (20Fr).  The study concluded that, "This is the first time a smaller diameter chest tube has been shown, with the ATC, to drain better than a larger diameter chest tube."  The MDEA recognition for PleuraFlow ATC follows a 2009 European Association of Cardiothoracic Surgeons award and a Design Distinction winner for the I.D. 2010 Annual Design Review.  

Xeridiem delivers exactly what each client requires to bring a complex, single use, minimally invasive medical device to market, on time, on budget.  These are our promises.  Xeridiem Medical Devices, founded as MRI 25 years ago, is backed by the technical and financial strength of our multinational parent company, Fenner plc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered MRI predicts outcomes in prostate cancer